Updated: May 19
Sequential launching medicines coupled with reference pricing is costing pharma companies hundreds of million dollars in forgone revenue.
OGT is proposing a simultaneous launch of new medicines in all considered markets with Optimal Global Launch Pricing.
This is a two part proposition:
- Pricing function - to keep regulatory agencies appraised of potential launch prices throughout the 12 years R&D process, with documents:
- INDP - Investigation New Drug Prices
- NDAP - New Drug Application Prices
- Actual launch optimal pricing
Next few blogs will detail and come up with live examples.